MediPaws
Specialty hospital / research center
1 current cancer treatment or research opportunity
About MediPaws
MediPaws is a veterinary referral hospital in Leichhardt, Sydney, with oncology and other specialist services. Its clinical research program currently enrolls eligible dogs with splenic haemangiosarcoma into a University of Melbourne-led multicentre treatment study.
Current MediPaws study →
Who the current listings are forDogs
Cancer types currently listedHemangiosarcoma
Current options at MediPaws
Open an option to see who may qualify, locations, costs or coverage, contact details and the official source.
Autologous tumour vaccine with doxorubicin after surgery for canine splenic hemangiosarcoma
University of Melbourne multicentre study — MediPaws Sydney site · Australia
Recruiting at MediPaws Sydney — participating site confirms active enrolment
What is being offered: Autologous tumour vaccine prepared from the resected splenic tumour, added to standard doxorubicin chemotherapy
Who may qualify: Confirmed cancer diagnosis required; No metastasis; Splenic primary; Post splenectomy; Planned doxorubicin
Costs / coverage: 🟡 The autologous tumour vaccine is free. Owners pay for standard veterinary care, including doxorubicin chemotherapy and associated costs.
Contact: MediPaws oncology, Dr Sonya Yu: 1800 678 387; contact via the MediPaws clinical research page
Location
- MediPaws, 233 Catherine Street, Leichhardt NSW 2040, Australia, Sydney, New South Wales
Official study / enrollment information →
Before you contact the center
A listing here does not mean every pet will qualify. Enrollment can change, and the study team makes the final decision after reviewing your pet’s diagnosis, records and previous treatment.
Have the pathology report, recent imaging and treatment history ready. Ask whether a referral is required, which visits must happen in person and what the study pays for before making travel plans.
Check all options for your pet →
Free to use. No registration or paid report.
